Literature DB >> 15194784

Antisense-mediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1-based vector results in severely attenuated mutants incapable of developing resistance.

Xiaobin Lu1, Qiao Yu, Gwendolyn K Binder, Ziping Chen, Tatiana Slepushkina, John Rossi, Boro Dropulic.   

Abstract

We have constructed a human immunodeficiency virus type 1 (HIV-1)-based lentiviral vector expressing a 937-base antisense sequence against the HIV-1 envelope gene. Transduction of CD4(+) T lymphocytes with this vector results in expression of the therapeutic antisense sequence and subsequent inhibition of productive HIV-1 replication. In this report, we examined the effect of antisense-mediated suppression on the potential development of virus escape mutants using a permissive T-cell line cultured under conditions that over serial passages specifically allowed for generation and amplification of mutants selected for by antisense pressure. In the resulting virus clones, we found a significant increase in the number of deletions at the envelope target region (91% compared to 27.5% in wild-type HIV). Deletions were most often greater than 1 kb in length. These data demonstrate for the first time that during antisense-mediated suppression of HIV, mutants develop as a direct result of selective pressure on the HIV genomic RNA. Interestingly, in clones where deletions were not observed, there was a high rate of A-G transitions in mutants at the antisense target region but not outside this region, which is consistent with those mutations that are predicted as a result of antisense-mediated modification of double-stranded RNA by the enzyme double-stranded RNA-specific adenosine deaminase. These clones were not found to be escape mutants, as their replicative ability was severely attenuated, and they did not replicate in the presence of vector.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15194784      PMCID: PMC421644          DOI: 10.1128/JVI.78.13.7079-7088.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

Review 1.  Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients.

Authors:  Barbara J Turner
Journal:  J Infect Dis       Date:  2002-05-15       Impact factor: 5.226

Review 2.  Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease.

Authors:  C Vigouroux; S Gharakhanian; Y Salhi; T H Nguyên; N Adda; W Rozenbaum; J Capeau
Journal:  Diabetes Metab       Date:  1999-11       Impact factor: 6.041

3.  Inhibition of human immunodeficiency virus type 1 by packageable, multigenic antisense RNA.

Authors:  M Shahabuddin; A S Khan
Journal:  Antisense Nucleic Acid Drug Dev       Date:  2000-06

4.  Hematologic recovery in mice transplanted with bone marrow stem cells expressing anti-human immunodeficiency virus genes.

Authors:  F Morel; S Salimi; J Markovits; T W Austin; I Plavec
Journal:  Hum Gene Ther       Date:  1999-11-20       Impact factor: 5.695

5.  Antisense RNA sequences targeting the 5' leader packaging signal region of human immunodeficiency virus type-1 inhibits viral replication at post-transcriptional stages of the life cycle.

Authors:  D R Chadwick; A M Lever
Journal:  Gene Ther       Date:  2000-08       Impact factor: 5.250

Review 6.  Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed?

Authors:  G M Behrens; M Stoll; R E Schmidt
Journal:  Drug Saf       Date:  2000-07       Impact factor: 5.606

7.  Search for the mechanism of genetic variation in the pro gene of human immunodeficiency virus.

Authors:  I M Rouzine; J M Coffin
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

8.  Antiretroviral-drug resistance among patients recently infected with HIV.

Authors:  Susan J Little; Sarah Holte; Jean-Pierre Routy; Eric S Daar; Marty Markowitz; Ann C Collier; Richard A Koup; John W Mellors; Elizabeth Connick; Brian Conway; Michael Kilby; Lei Wang; Jeannette M Whitcomb; Nicholas S Hellmann; Douglas D Richman
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

9.  Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference.

Authors:  Glen A Coburn; Bryan R Cullen
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  Modulation of HIV-1 replication by RNA interference.

Authors:  Jean-Marc Jacque; Karine Triques; Mario Stevenson
Journal:  Nature       Date:  2002-06-26       Impact factor: 69.504

View more
  36 in total

1.  Zinc finger protein designed to target 2-long terminal repeat junctions interferes with human immunodeficiency virus integration.

Authors:  Supachai Sakkhachornphop; Carlos F Barbas; Rassamee Keawvichit; Kanlaya Wongworapat; Chatchai Tayapiwatana
Journal:  Hum Gene Ther       Date:  2012-05-08       Impact factor: 5.695

2.  A spatially varying two-sample recombinant coalescent, with applications to HIV escape response.

Authors:  Alexander Braunstein; Shane T Jensen; Zhi Wei; Jon D McAuliffe
Journal:  Adv Neural Inf Process Syst       Date:  2008

3.  Regulation of Antisense Transcription by NuA4 Histone Acetyltransferase and Other Chromatin Regulatory Factors.

Authors:  Bhawana Uprety; Amala Kaja; Jannatul Ferdoush; Rwik Sen; Sukesh R Bhaumik
Journal:  Mol Cell Biol       Date:  2016-01-11       Impact factor: 4.272

4.  Computational design of antiviral RNA interference strategies that resist human immunodeficiency virus escape.

Authors:  Joshua N Leonard; David V Schaffer
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

5.  Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells.

Authors:  Gary P Wang; Bruce L Levine; Gwendolyn K Binder; Charles C Berry; Nirav Malani; Gary McGarrity; Pablo Tebas; Carl H June; Frederic D Bushman
Journal:  Mol Ther       Date:  2009-03-03       Impact factor: 11.454

Review 6.  Antisense RNA: the new favorite in genetic research.

Authors:  Jian-Zhong Xu; Jun-Lan Zhang; Wei-Guo Zhang
Journal:  J Zhejiang Univ Sci B       Date:  2018 Oct.       Impact factor: 3.066

Review 7.  HIV-1 reverse transcription.

Authors:  Wei-Shau Hu; Stephen H Hughes
Journal:  Cold Spring Harb Perspect Med       Date:  2012-10-01       Impact factor: 6.915

8.  Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV.

Authors:  Pablo Tebas; David Stein; Gwendolyn Binder-Scholl; Rithun Mukherjee; Troy Brady; Tessio Rebello; Laurent Humeau; Michael Kalos; Emmanouil Papasavvas; Luis J Montaner; Daniel Schullery; Farida Shaheen; Andrea L Brennan; Zhaohui Zheng; Julio Cotte; Vladimir Slepushkin; Elizabeth Veloso; Adonna Mackley; Wei-Ting Hwang; Faten Aberra; Jenny Zhan; Jean Boyer; Ronald G Collman; Frederic D Bushman; Bruce L Levine; Carl H June
Journal:  Blood       Date:  2012-12-20       Impact factor: 22.113

9.  Newly designed six-membered azasugar nucleotide-containing phosphorothioate oligonucleotides as potent human immunodeficiency virus type 1 inhibitors.

Authors:  Dong-Seong Lee; Kyeong-Eun Jung; Cheol-Hee Yoon; Hong Lim; Yong-Soo Bae
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

10.  Survival of the fittest: positive selection of CD4+ T cells expressing a membrane-bound fusion inhibitor following HIV-1 infection.

Authors:  Janine Kimpel; Stephen E Braun; Gang Qiu; Fay Eng Wong; Michelle Conolle; Jörn E Schmitz; Christian Brendel; Laurent M Humeau; Boro Dropulic; John J Rossi; Annemarie Berger; Dorothee von Laer; R Paul Johnson
Journal:  PLoS One       Date:  2010-08-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.